PDEX Stock Analysis: Pro-Dex | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 202m USD | 12M Return: 134.8% | US74265M2052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.99M
EPS Trend: 92.3%
Qual. Beats: 0
Rev. Trend: 99.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pro-Dex, Inc. (NASDAQ: PDEX) is a California-based medical device company founded in 1978 and headquartered in Irvine. The company designs, manufactures, and repairs powered surgical instruments-including battery-powered and electric drivers and shavers-on a contract basis for medical device original equipment manufacturers (OEMs) serving the orthopedic, thoracic, and craniomaxillofacial markets. Beyond its core medical business, Pro-Dex also produces rotary air motors for industrial customers and precision machined parts for the aerospace and defense sectors, while offering engineering, quality, and regulatory consulting services to its OEM clients.
Pro-Dex operates within the Health Care Equipment sub-industry (GICS) and functions as a specialized medtech outsource partner, a business model in which smaller firms handle design, engineering, and production for larger medical device companies rather than selling branded end products. With a market capitalization of approximately $205 million (micro-cap), the company has been publicly traded since 1995 and sells into hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations worldwide.
- Orthopedic surgical volumes rise, driving powered instrument demand
- Medical device OEM contract awards accelerate top-line revenue growth
- Aerospace and defense machining segment expands on rising defense spending
| Net Income: 13.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 14.03 > 1.0 |
| NWC/Revenue: 51.92% < 20% (prev 49.05%; Δ 2.87% < -1%) |
| CFO/TA 0.10 > 3% & CFO 7.24m > Net Income 13.7m |
| Net Debt (10.2m) to EBITDA (20.0m): 0.51 < 3 |
| Current Ratio: 4.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.32m) vs 12m ago -1.00% < -2% |
| Gross Margin: 31.38% > 18% (prev 29.30%; Δ 2.08% > 0.5%) |
| Asset Turnover: 114.3% > 50% (prev 108.8%; Δ 5.46% > 0%) |
| Interest Coverage Ratio: 22.86 > 6 (EBIT TTM 18.6m / Interest Expense TTM 812k) |
| A: 0.54 (Total Current Assets 53.2m - Total Current Liabilities 13.0m) / Total Assets 74.5m |
| B: 0.64 (Retained Earnings 47.6m / Total Assets 74.5m) |
| C: 0.27 (EBIT TTM 18.6m / Avg Total Assets 67.9m) |
| D: 1.77 (Book Value of Equity 47.6m / Total Liabilities 26.9m) |
| Altman-Z'' = 9.33 = AAA |
| DSRI: 1.04 (Receivables 21.2m/17.5m, Revenue 77.5m/66.6m) |
| GMI: 0.93 (GM 29.30% / 31.38%) |
| AQI: 1.32 (AQ_t 0.28 / AQ_t-1 0.21) |
| SGI: 1.16 (Revenue 77.5m / 66.6m) |
| TATA: 0.09 (NI 13.7m - CFO 7.24m) / TA 74.5m) |
| Beneish M = -2.73 (Cap -4..+1) = A |
As of October 14, 2026, the stock is trading at USD 62.27 with a total of 29,092 shares traded. Over the past week, the price has changed by -4.08%, over one month by -6.45%, over three months by +1.17% and over the past year by +134.80%.
Current recommended Stop Loss: 57.60 (which is 7.5% or 1.4 ATR below the current price).
Pro-Dex has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy PDEX.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 74 | 18.8% |
P/E Trailing = 15.1675
P/E Forward = 23.4192
P/S = 2.6054
P/B = 4.8696
Revenue TTM = 77.5m USD
EBIT TTM = 18.6m USD
EBITDA TTM = 20.0m USD
Long Term Debt = 13.3m USD (from longTermDebt, last quarter)
Short Term Debt = 4.21m USD (from shortTermDebt, last quarter)
Debt = 19.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.47m
Net Debt = 10.2m USD (calculated: Debt 19.6m - CCE 9.34m)
Enterprise Value = 212.3m USD (202.0m + Debt 19.6m - CCE 9.34m)
Interest Coverage Ratio = 22.86 (Ebit TTM 18.6m / Interest Expense TTM 812k)
EV/FCF = 30.80x (Enterprise Value 212.3m / FCF TTM 6.89m)
FCF Yield = 3.25% (FCF TTM 6.89m / Enterprise Value 212.3m)
FCF Margin = 8.89% (FCF TTM 6.89m / Revenue TTM 77.5m)
Net Margin = 17.62% (Net Income TTM 13.7m / Revenue TTM 77.5m)
Gross Margin = 31.38% ((Revenue TTM 77.5m - Cost of Revenue TTM 53.2m) / Revenue TTM)
Gross Margin QoQ = 34.75% (prev 30.74%)
Tobins Q-Ratio = 2.85 (Enterprise Value 212.3m / Total Assets 74.5m)
Interest Expense / Debt = 4.15% (Interest Expense 812k / Debt 19.6m)
Taxrate = 24.16% (4.35m / 18.0m)
NOPAT = 14.1m (EBIT 18.6m * (1 - 24.16%))
Current Ratio = 4.10 (Total Current Assets 53.2m / Total Current Liabilities 13.0m)
Debt / Equity = 0.41 (Debt 19.6m / totalStockholderEquity, last quarter 47.6m)
Debt / EBITDA = 0.51 (Net Debt 10.2m / EBITDA 20.0m)
Debt / FCF = 1.48 (Net Debt 10.2m / FCF TTM 6.89m)
Total Stockholder Equity = 44.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.14% (Net Income 13.7m / Total Assets 74.5m)
RoE = 31.05% (Net Income TTM 13.7m / Total Stockholder Equity 44.0m)
RoCE = 32.42% (EBIT 18.6m / Capital Employed (Equity 44.0m + L.T.Debt 13.3m))
RoIC = 22.76% (NOPAT 14.1m / Invested Capital 61.9m)
WACC = 6.94% (E(202.0m)/V(221.6m) * Re(7.31%) + D(19.6m)/V(221.6m) * Rd(4.15%) * (1-Tc(0.24)))
Discount Rate = 7.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -72.92 | Cagr: -2.65%
[DCF] Terminal Value 75.44% ; FCFF base≈6.89m ; Y1≈6.92m ; Y5≈7.33m
[DCF] Fair Price = 32.10 (EV 114.0m - Net Debt 10.2m = Equity 103.8m / Shares 3.23m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 92.28 | EPS CAGR: 112.0% | SUE: 0.62 | # QB: 0
Revenue Correlation: 99.31 | Revenue CAGR: 21.53% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.67 | Chg30d=+1.52% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-12-31): EPS=0.72 | Chg30d=+4.35% | Revisions=+25% | Analysts=1
EPS current Year (2027-06-30): EPS=3.09 | Chg30d=+11.15% | Revisions=+25% | GrowthEPS=-25.0% | GrowthRev=+6.6%
EPS next Year (2028-06-30): EPS=3.36 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+8.7% | GrowthRev=+5.0%